RepliCel Life Sciences Significato medio
Cos'è Significato medio di RepliCel Life Sciences?
Significato medio di RepliCel Life Sciences, Inc. è 2.00
Qual è la definizione di Significato medio?
La media di raccomandazione è la media delle valutazioni degli analisti sul titolo che vanno da 1,0 (strong buy) a 5.0 (strong sell).
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
Significato medio di aziende nel Health Care settore su TSXV rispetto a RepliCel Life Sciences
Cosa fa RepliCel Life Sciences?
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Aziende con significato medio simili a RepliCel Life Sciences
- Cabot Oil & Gas ha Significato medio di 1.96
- Truist ha Significato medio di 1.96
- Delta Air Lines ha Significato medio di 1.96
- Discover Services ha Significato medio di 1.96
- United Micro Electronics ha Significato medio di 1.96
- Tapestry Inc ha Significato medio di 1.97
- RepliCel Life Sciences ha Significato medio di 2.00
- Trip.com Ltd ha Significato medio di 2.03
- Sherwin-Williams Co ha Significato medio di 2.03
- Canadian Pacific Kansas City ha Significato medio di 2.03
- Arista Networks Inc ha Significato medio di 2.03
- Anheuser-Busch InBev SA/NV ha Significato medio di 2.03
- Celanese Corp ha Significato medio di 2.04